Pharmaceutical Technology11 小时
Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints
Adaptimmune’s Phase II IGNYTE-ESO trial investigating experimental T cell therapy lete-cel has achieved its primary endpoint.
Protein Expression Market to Hit USD 4.82 Billion by 2029 with 7.1% CAGR | MarketsandMarkets™
The global protein expression market is expected to reach USD 4.82 billion in 2029 from USD 3.41 billion in 2024 at a CAGR of ...